Peptide Therapy

Retatrutide is a novel investigational peptide currently under study as a triple receptor agonist, targeting GLP-1, GIP, and glucagon receptors. Preclinical and early clinical research has focused on its potential impact on metabolic regulation, including pathways related to energy balance, insulin sensitivity, and body weight management. Scientific interest continues to grow regarding its comparative activity to other GLP-1–based compounds in research models.

Tirzepatide is a synthetic peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been studied in preclinical and clinical research for its effects on glycemic regulation, insulin sensitivity, appetite signaling, and metabolic function. Research models have explored its potential impact on weight modulation and energy balance, particularly in the context of metabolic disorders.

The BPC-157/TB-500 Mix combines equal concentrations of two synthetic peptides that have been studied for their  synergistic effects on tissue regeneration and cellular recovery. Preclinical models suggest this blend supports processes related to inflammation modulation, muscle and joint repair, and overall recovery dynamics.

Semaglutide is a synthetic peptide that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. In preclinical and clinical research, it has been investigated for its potential to influence glucose regulation, appetite signaling, and gastrointestinal motility. Studies have focused on its effects in models of metabolic function, including energy balance and insulin sensitivity.

GHK-Cu is a naturally occurring copper-binding peptide that has been studied for its potential role in tissue remodeling, collagen synthesis, and cellular regeneration. In preclinical research, it has demonstrated effects on pathways associated with skin repair, wound healing, and inflammatory modulation.

A Retatrutide and Tirzepatide blend combines the triple-agonist action of investigational Retatrutide (GLP-1, GIP, glucagon) with the dual-agonist action of FDA-approved Tirzepatide (GLP-1, GIP) for potentially enhanced weight loss and metabolic benefits, targeting multiple hormone pathways to improve satiety, blood sugar control, and fat burning beyond what either drug offers alone.

Glow Pro is a research formulation combining GHK-Cu, TB-500, and BPC-157. This synergistic blend has been studied in preclinical models for its potential to support tissue regeneration, modulate inflammatory responses, and influence cellular processes involved in repair. Research interest has centered around applications in skin health, recovery, and tissue resilience.  This is the go to stack for those wanting to keep their youthful look. 

MOTS-C is a mitochondrial-derived peptide that has been studied for its potential role in regulating metabolic processes, including glucose and lipid metabolism, at the cellular level. Preclinical research suggests it may influence mitochondrial function, energy balance, and stress response pathways. Investigations continue into its relevance in models of aging, endurance, and metabolic health.

NAD+ is a critical coenzyme involved in numerous cellular processes, including mitochondrial energy production, DNA repair, and cell signaling. Research has explored its role in metabolic regulation and cellular resilience, particularly in models of aging and stress response. Scientific interest continues to grow around its potential impact on neurological function, longevity pathways, and cellular maintenance mechanisms.

IGF-1 LR3 is a long-acting analogue of insulin-like growth factor-1 (IGF-1), modified to extend its half-life and enhance stability in experimental settings. It has been studied in preclinical research for its potential to influence pathways related to muscle tissue growth, protein synthesis, and cellular repair. Interest in this compound often centers on its role in models exploring anabolic activity and tissue regeneration mechanisms.

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH), studied for its ability to stimulate endogenous growth hormone production (it shreds visceral fat). Initially developed and approved for the reduction of visceral adipose tissue in specific clinical populations, it is now being investigated in preclinical and clinical research settings for its potential effects on fat metabolism, muscle physiology, cognitive processes, and metabolic regulation. Studies continue to ex